Stephanie Swope
Nurse Practitioner · Seneca, PANPI 1811439045
Payments from drug & device makers
Across 91 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$248
- AbbVie$243
- Astellas Pharma US Inc$210
- Novo Nordisk$172
- GSK$115
- Exact Sciences$97
- plus $614 from 15 others
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$1,67599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $248 |
| AbbVie | 15 | $243 |
| Astellas Pharma US Inc | 9 | $210 |
| Novo Nordisk | 11 | $172 |
| GSK | 6 | $115 |
| Exact Sciences | 5 | $97 |
| Bayer | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Lilly USA, LLC | 5 | $76 |
| Shield Therapeutics Inc | 4 | $69 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Mylan Specialty L.p. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Pfizer | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Ardelyx, Inc. | 1 | $23 |
| Merck | 1 | $18 |
| Amgen | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,699 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 39 | $41,547 |
| Gabapentin | 46 | $812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $534 |
| Cephalexin | 27 | $408 |
| Tramadol Hcl | 39 | $389 |
| Famotidine | 17 | $335 |
| Levothyroxine Sodium | 47 | $327 |
| Lisinopril | 22 | $308 |
| Fluoxetine Hcl | 11 | $297 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $285 |
| Levocetirizine Dihydrochloride | 12 | $278 |
| Fluticasone Propionate | 23 | $225 |
| Escitalopram Oxalate | 15 | $225 |
| Azithromycin | 39 | $210 |
| Oxycodone Hcl | 11 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $248 | $41,54739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Seneca
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.